arrow
A

Alexandre V. Hirayama

Fred Hutchinson Cancer Center
H指数:21
被引数:3,864

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early neurologic response predicts outcomes after anakinra for immune effector cell-associated neurotoxicity syndrome

早期神经系统反应预测anakinra治疗免疫效应细胞相关神经毒性综合征的结局

2026-06-020
OAAI
Extramedullary disease is associated with severe toxicities following B-cell maturation antigen CAR T-cell therapy in multiple myeloma

髓外疾病与多发性骨髓瘤中B细胞成熟抗原CAR T细胞疗法后的严重毒性与相关。

2025-12-015
OA
Eomesodermin+ CD4+ T cells are critical for curative immunotherapy outcomes

Eomesodermin<sup>+</sup> CD4<sup>+</sup> T细胞对于治愈性免疫治疗效果至关重要

Immunity
IF26.3
2025-10-020
PRE
Opportunities to improve antibiotic stewardship, and identification of blood biomarkers associated with bacteremia following CAR-T cell therapy

改善抗生素合理使用的机会,以及CAR-T细胞疗法后菌血症相关血液生物标志物的鉴定

2025-07-310
PRE
Low Peripheral Blood Counts and Elevated Proinflammatory Cytokines Signal a Poor CD19 Chimeric Antigen Receptor T-cell Response in Acute Lymphoblastic Leukemia

外周血计数低和升高的促炎细胞因子预示急性淋巴细胞白血病中CD19嵌合抗原受体T细胞反应不良

2025-05-200
OAAI
TNFα Apoptotic Signaling By Antigen-Engaged CAR T-Cells Mediates Clearance of Target Antigen-Negative Acute Myeloid Leukemia

TNFα介导的抗原激活CAR T细胞凋亡信号清除靶抗原阴性的急性髓系白血病

BLOOD
IF23.1
2024-11-050
PRE
Histone marks identify novel transcription factors that parse CAR-T subset-of-origin, clinical potential and expansion

组蛋白标记识别解析car-t起源子集,临床潜力和扩展的新型转录因子

2024-09-270
OAAI
PD-L1+ macrophage and tumor cell abundance and proximity to T cells in the pretreatment large B-cell lymphoma microenvironment impact CD19 CAR-T cell immunotherapy efficacy

PD-L1巨噬细胞和肿瘤细胞的丰度以及与T细胞的邻近性在预处理大b细胞淋巴瘤微环境中影响CD19 car-t细胞免疫治疗的疗效

2024-08-071
OAAI
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphoma

anti-PD-L1抗体起始时间影响CD19 car-t细胞治疗大b细胞淋巴瘤的疗效/毒性

2024-01-2311
OAAI
Factors associated with long-term outcomes of CD19 CAR T-cell therapy for relapsed/refractory CLL

与CD19 CAR T细胞治疗复发/难治性CLL的长期结果相关的因素

2023-11-177
OAAI
Anakinra for Refractory Cytokine Release Syndrome or Immune Effector Cell-Associated Neurotoxicity Syndrome after Chimeric Antigen Receptor T Cell Therapy

Anakinra治疗嵌合抗原受体T细胞治疗后难治性细胞因子释放综合征或免疫效应细胞相关神经毒性综合征

2023-07-0160
OAAI
Antibodies against vaccine-preventable infections after CAR-T cell therapy for B cell malignancies

B细胞恶性肿瘤car-t细胞治疗后疫苗可预防感染的抗体

2021-04-2957
OA
Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes

重症和危重新型冠状病毒肺炎的细胞因子升高: 快速系统评价,荟萃分析以及与其他炎症综合征的比较

2020-12-01639
OAAI